Galectin Therapeutics Inc
galectintherapeutics.comGalectin Therapeutics Inc (NASDAQ: GALT) is a clinical-stage biopharmaceutical company developing carbohydrate-based therapies targeting galectin proteins. The company generates no product revenue and funds operations entirely through external financing, primarily a convertible line of credit provided by its chairman, who extended $30,000,000 in proceeds under that facility in both FY2024 and FY2023. GALT's lead drug candidate is belapectin, which is the focus of the NAVIGATE clinical trial. Research and development expenses totaled $36.6 million in FY2024, up 13.8% from $32.1 million in FY2023, driven by NAVIGATE trial activities and contract manufacturing costs for belapectin. General and administrative expenses were $5.9 million in FY2024. The company is headquartered in Norcross, Georgia, with office space leased at approximately $5,400 per month under an amended lease running through April 30, 2026. Manufacturing is outsourced to contract manufacturers on a purchase-order basis, with no internal production facilities.
Products & Services
Belapectin, a carbohydrate-based drug candidate targeting galectin proteins, currently in the NAVIGATE clinical trial as of FY2024. No approved or commercialized products as of the filing date.
Revenue Model
No product revenue. Operations are financed through a related-party convertible line of credit from the company's chairman ($30,000,000 drawn in FY2024 and $30,000,000 drawn in FY2023), proceeds from stock option and warrant exercises, and stock issuances.
Customers & Markets
No commercial customers. End market is clinical development targeting liver or fibrosis-related disease, inferred from galectin biology, though the specific indication is not detailed in the provided excerpts.
Geographic Exposure
Headquartered in Norcross, Georgia, with a prior research and lab space in Natick, Massachusetts. No geographic revenue breakdown disclosed, as the company has no product revenue.
Financial Snapshot
Loading...
